

SAFETY DATA SHEET



Antibodies Reagent IVD

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : Antibodies Reagent IVD

Part no. : 8920007, 8920012, 8920015, 8920016, 8920017, 8920018, 8920022, 8920023, 8920036, 8920043, 8920045, 8920048, 8920049, 8920050, 8920053, 8920054, 8920064, 8920070, 8920084, 8920085, 8920086, 8920100, 8920108, 8920109, 8920119, 8920120, 8920123, 8920130, 8920132, 8920140, 8920144, 8920158, 8920200, 8920216, 8920230, 8920248, 8920249, 8920255, 8920261, 8920262, 8920263, 8920264, 8920265, 8920266, 8920267, 8920268, 8920269, 8920270, 8920271, 8920272, 8920273, 8920274, 8920276, 8920277, 8920278, 8920279, 8920280, 8920282, 8920331, 8920959, 8921013, 8921014, 8921015, 8921016, 8921017, 8921018, 8921019, 8921020, 8921021, 8921022, 8921023, 8921024, 8921025, 8921029, 8921030, 8921031, 8921032, 8921033, 8921034, 8921035, 8921036, 8921037, 8921042, 8921043, 8921044, 8921045, 8929995, 8929996, 8929997, 8929998, 8929999, 8930007, 8930012, 8930015, 8930016, 8930017, 8930018, 8930022, 8930023, 8930036, 8930043, 8930045, 8930048, 8930049, 8930050, 8930053, 8930054, 8930064, 8930084, 8930085, 8930086, 8930108, 8930109, 8930114, 8930119, 8930120, 8930123, 8930130, 8930132, 8930144, 8930158, 8930200, 8930216, 8930230, 8930248, 8930249, 8930261, 8930262, 8930263, 8930264, 8930265, 8930266, 8930267, 8930268, 8930269, 8930270, 8930271, 8930272, 8930273, 8930274, 8930276, 8930277, 8930278, 8930279, 8930280, 8930282, 8930331, 8930959, 8931013, 8931014, 8931015, 8931016, 8931017, 8931018, 8931019, 8931020, 8931021, 8931022, 8931023, 8931024, 8931025, 8931029, 8931030, 8931031, 8931032, 8931033, 8931034, 8931035, 8931036, 8931037, 8931042, 8931043, 8931044, 8931045, 8939995, 8939996, 8939997, 8939998, 8939999, 8921066, 8921067, 8921068, 8920698, 8920185, 8931066, 8931067, 8931068, 8930698, 8930185, 8921054, 8931054, 8921050, 8931050, 8921049, 8931049, 8920037, 8930037, 8920114, 8920702, 8920705, 8920796, 8921051, 8930702, 8930705, 8930796, 8931051

1.2 Relevant identified uses of the substance or mixture and uses advised against

Material uses : For In Vitro Diagnostic Use

8920007 APC Mouse anti-human CD19

8920012 CD4/CD8/CD3 mouse anti-human

8920015 PE-Cy7 Mouse anti-human CD19

8920016 FITC Mouse anti-human CD19

8920017 PE Mouse anti-human CD19

8920018 PE Mouse anti-human CD1a

8920022 FITC Mouse anti-human CD2

8920023 PE Mouse anti-human CD2

8920036 PE Mouse anti-human CD7

8920043 FITC Mouse anti-human CD10

8920045 APC Mouse anti-human CD10

8920048 PE Mouse anti-human CD11b

8920049 APC Mouse anti-human CD11b

8920050 PE Mouse anti-human CD11c

8920053 PE Mouse anti-human CD13

8920054 PE-Cyanine 7 Mouse anti-human CD13

8920064 FITC Mouse anti-human CD16

8920070 FITC Mouse anti-human CD20

8920084 PE Mouse anti-human CD25

8920085 APC Mouse anti-human CD25

8920086 PE-Cyanine 7 Mouse anti-human CD25

8920100 PE Mouse anti-human CD34

8920108 FITC Mouse anti-human CD38

8920109 PE Mouse anti-human CD38

8920119 PE Mouse anti-human CD64

Antibodies Reagent IVD

**SECTION 1: Identification of the substance/mixture and of the company/
undertaking**

8920120	FITC Mouse anti-human CD71
8920123	PE Mouse anti-human CD79a
8920130	PE Mouse anti-human CD117
8920132	PE-Cyanine 7 Mouse anti-human CD117
8920140	APC Mouse anti-human CD138
8920144	APC Mouse anti-human HLA-DR
8920158	FITC Mouse anti-human ZAP-70
8920200	PE Mouse anti-human CD5
8920216	APC-Cyanine 7 Mouse anti-human HLA-DR
8920230	APC Mouse anti-human CD5
8920248	APC Mouse anti-human CD61
8920249	FITC Mouse anti-human CD15
8920255	PE Mouse anti-human CD22
8920261	FITC Mouse anti-human MPO
8920262	APC Mouse anti-human CD79a
8920263	PE-Cyanine 7 Mouse anti-human CD3
8920264	APC-Cyanine 7 Mouse anti-human CD45
8920265	APC-Cyanine 7 Mouse anti-human CD8
8920266	PE-Cyanine 7 Mouse anti-human CD23
8920267	APC-Cyanine 7 Mouse anti-human CD36
8920268	APC-Cyanine 7 Mouse anti-human CD38
8920269	PE-Cyanine 7 Mouse anti-human CD45RA
8920270	PE Mouse anti-human CD45RO
8920271	APC Mouse anti-human CD45RO
8920272	FITC Mouse anti-human CD62P
8920273	PE Mouse anti-human CD69
8920274	PE Mouse anti-human CD127
8920276	FITC Mouse anti-human CD14
8920277	APC Mouse anti-human CD14
8920278	APC Mouse anti-human CD56
8920279	APC-Cyanine 7 Mouse anti-human CD56
8920280	PE-Cyanine 7 Mouse anti-human CD33
8920282	APC Mouse anti-human CD33
8920331	PE-Cyanine 7 Mouse anti-human CD11c
8920959	FITC Mouse anti-human CD45RA
8921013	PerCP-Cyanine 5.5 Mouse anti-human CD45
8921014	FITC Mouse anti-human CD45
8921015	PerCP-Cyanine 5.5 Mouse anti-CD3
8921016	FITC Mouse anti-human CD3
8921017	PerCP Mouse anti-human CD45
8921018	FITC Mouse anti-human CD4
8921019	APC Mouse anti-human CD4
8921020	PE-Cyanine 7 Mouse anti-human CD4
8921021	PE Mouse anti-human CD4
8921022	PE Mouse anti-human CD8
8921023	FITC Mouse anti-human CD8
8921024	PE-Cyanine 7 Mouse anti-human CD8
8921025	APC Mouse anti-human CD8
8921029	APC-Cyanine7 Mouse anti-human CD2
8921030	PerCP-Cyanine5.5 Mouse anti-human CD33
8921031	APC-Fire™750 Mouse anti-human CD117
8921032	APC-Fire™750 Mouse anti-human HLA-DR
8921033	APC-Fire™750 Mouse anti-human CD3
8921034	PerCP-Cyanine5.5 Mouse anti-human CD4
8921035	PE-Cyanine7 Mouse anti-human CD7
8921036	APC-Fire™750 Mouse anti-human CD10
8921037	APC Mouse anti-human CD13
8921042	PE Mouse anti-human CD23
8921043	APC Mouse anti-human CD36
8921044	PE-Cyanine 7 Mouse anti-human CD56
8921045	PE-Dazzle™594 Mouse anti-human CD56

Antibodies Reagent IVD

**SECTION 1: Identification of the substance/mixture and of the company/
undertaking**

8929995	PE Mouse anti-human CD59
8929996	FITC Mouse anti-human CD14
8929997	PE Mouse anti-human CD64
8929998	PerCP Mouse anti-human CD45
8929999	APC Mouse anti-human HLA-DR
8930007	APC Mouse anti-human CD19
8930012	CD4/CD8/CD3 mouse anti-human
8930015	PE-Cyanine 7 Mouse anti-human CD19
8930016	FITC Mouse anti-human CD19
8930017	PE Mouse anti-human CD19
8930018	PE Mouse anti-human CD1a
8930022	FITC Mouse anti-human CD2
8930023	PE Mouse anti-human CD2
8930036	PE Mouse anti-human CD7
8930043	FITC Mouse anti-human CD10
8930045	APC Mouse anti-human CD10
8930048	PE Mouse anti-human CD11b
8930049	APC Mouse anti-human CD11b
8930050	PE Mouse anti-human CD11c
8930053	PE Mouse anti-human CD13
8930054	PE-Cyanine 7 Mouse anti-human CD13
8930064	FITC Mouse anti-human CD16
8930084	PE Mouse anti-human CD25
8930085	APC Mouse anti-human CD25
8930086	PE-Cyanine 7 Mouse anti-human CD25
8930108	FITC Mouse anti-human CD38
8930109	PE Mouse anti-human CD38
8930114	APC Mouse anti-human CD56
8930119	PE Mouse anti-human CD64
8930120	FITC Mouse anti-human CD71
8930123	PE Mouse anti-human CD79a
8930130	PE Mouse anti-human CD117
8930132	PE-Cyanine 7 Mouse anti-human CD117
8930144	APC Mouse anti-human HLA-DR
8930158	FITC Mouse anti-human ZAP-70
8930200	PE Mouse anti-human CD5
8930216	APC-Cyanine 7 Mouse anti-human HLA-DR
8930230	APC Mouse anti-human CD5
8930248	APC Mouse anti-human CD61
8930249	FITC Mouse anti-human CD15
8930261	FITC Mouse anti-human MPO
8930262	APC Mouse anti-human CD79a
8930263	PE-Cyanine 7 Mouse anti-human CD3
8930264	APC-Cyanine 7 Mouse anti-human CD45
8930265	APC-Cyanine 7 Mouse anti-human CD8
8930266	PE-Cyanine 7 Mouse anti-human CD23
8930267	APC-Cyanine 7 Mouse anti-human CD36
8930268	APC-Cyanine 7 Mouse anti-human CD38
8930269	PE-Cyanine 7 Mouse anti-human CD45RA
8930270	PE Mouse anti-human CD45RO
8930271	APC Mouse anti-human CD45RO
8930272	FITC Mouse anti-human CD62P
8930273	PE Mouse anti-human CD69
8930274	PE Mouse anti-human CD127
8930276	FITC Mouse anti-human CD14
8930277	APC Mouse anti-human CD14
8930278	APC Mouse anti-human CD56
8930279	APC-Cyanine 7 Mouse anti-human CD56
8930280	PE-Cyanine 7 Mouse anti-human CD33
8930282	APC Mouse anti-human CD33
8930331	PE-Cyanine 7 Mouse anti-human CD11c

Antibodies Reagent IVD

**SECTION 1: Identification of the substance/mixture and of the company/
undertaking**

8930959	FITC Mouse anti-human CD45RA
8931013	PerCP-Cyanine 5.5 Mouse anti-human CD45
8931014	FITC Mouse anti-human CD45
8931015	PerCP-Cyanine 5.5 Mouse anti-human-CD3
8931016	FITC Mouse anti-human CD3
8931017	PerCP Mouse anti-human CD45
8931018	FITC Mouse anti-human CD4
8931019	APC Mouse anti-human CD4
8931020	PE-Cyanine 7 Mouse anti-human CD4
8931021	PE Mouse anti-human CD4
8931022	PE Mouse anti-human CD8
8931023	FITC Mouse anti-human CD8
8931024	PE-Cyanine 7 Mouse anti-human CD8
8931025	APC Mouse anti-human CD8
8931029	APC-Cyanine7 Mouse anti-human CD2
8931030	PerCP-Cyanine5.5 Mouse anti-human CD33
8931031	APC-Fire™750 Mouse anti-human CD117
8931032	APC-Fire™750 Mouse anti-human HLA-DR
8931033	APC-Fire™750 Mouse anti-human CD3
8931034	PerCP-Cyanine5.5 Mouse anti-human CD4
8931035	PE-Cyanine7 Mouse anti-human CD7
8931036	APC-Fire™750 Mouse anti-human CD10
8931037	APC Mouse anti-human CD13
8931042	PE Mouse anti-human CD23
8931043	APC Mouse anti-human CD36
8931044	PE-Cyanine 7 Mouse anti-human CD56
8931045	PE-Dazzle™594 Mouse anti-human CD56
8939995	PE Mouse anti-human CD59
8939996	FITC Mouse anti-human CD14
8939997	PE Mouse anti-human CD64
8939998	PerCP Mouse anti-human CD45
8939999	APC Mouse anti-human HLA-DR
8921066	PE-Cyanine7 Mouse anti-human CD28
8921067	PE-Cyanine5 Mouse anti-human CD28
8921068	APC-Cyanine7 Mouse anti-human CD28
8920698	PE-Cyanine7 Mouse anti-human CD41
8920185	FITC Mouse anti-human CD41
8931066	PE-Cyanine7 Mouse anti-human CD28
8931067	PE-Cyanine5 Mouse anti-human CD28
8931068	APC-Cyanine7 Mouse anti-human CD28
8930698	PE-Cyanine7 Mouse anti-human CD41
8930185	FITC Mouse anti-human CD41
8921054	APC-Cyanine7 Mouse anti-human CD13
8931054	APC-Cyanine7 Mouse anti-human CD13
8921050	PE-Cyanine5 Mouse anti-human CD7
8931050	PE-Cyanine5 Mouse anti-human CD7
8921049	PE-Cyanine5 Mouse anti-human CD10
8931049	PE-Cyanine5 Mouse anti-human CD10
8920037	APC Mouse anti-human CD7
8930037	APC Mouse anti-human CD7
8920114	APC Mouse anti-human CD56
8920702	APC-Cyanine7 Mouse anti-human CD42b
8920705	PE Mouse anti-human CD42b
8920796	APC Mouse anti-human CD58
8921051	PerCP-Cyanine5.5 Mouse anti-human CD71
8930702	APC-Cyanine7 Mouse anti-human CD42b
8930705	PE Mouse anti-human CD42b
8930796	APC Mouse anti-human CD58
8931051	PerCP-Cyanine5.5 Mouse anti-human CD71

1.3 Details of the supplier of the safety data sheet

Antibodies Reagent IVD

**SECTION 1: Identification of the substance/mixture and of the company/
undertaking**

Agilent Technologies Manufacturing GmbH & Co. KG
Hewlett-Packard-Str. 8
76337 Waldbronn
Germany
0800 603 1000

e-mail address of person responsible for this SDS : pdl-msds_author@agilent.com

1.4 Emergency telephone number

Emergency telephone number (with hours of operation) : CHEMTREC®: +(44)-870-8200418

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

H412 LONG-TERM (CHRONIC) AQUATIC HAZARD Category 3

Ingredients of unknown toxicity : Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 1 - 10%

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Signal word : No signal word.

Hazard statements : H412 - Harmful to aquatic life with long lasting effects.

Precautionary statements

Prevention : P273 - Avoid release to the environment.

Response : Not applicable.

Storage : Not applicable.

Disposal : P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.

Supplemental label elements : Not applicable.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles : Not applicable.

Special packaging requirements

Tactile warning of danger : Not applicable.

2.3 Other hazards

Antibodies Reagent IVD

SECTION 2: Hazards identification

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do not result in classification : None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture

Product/ingredient name	Identifiers	%	Regulation (EC) No. 1272/2008 [CLP]	Type
Sodium azide	EC: 247-852-1 CAS: 26628-22-8 Index: 011-004-00-7	≤1.3	Acute Tox. 2, H300 Aquatic Acute 1, H400 (M=1) Aquatic Chronic 1, H410 (M=1) EUH032 See Section 16 for the full text of the H statements declared above.	[1] [2]

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

- [1] Substance classified with a health or environmental hazard
 - [2] Substance with a workplace exposure limit
 - [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
 - [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
 - [5] Substance of equivalent concern
 - [6] Additional disclosure due to company policy
- Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur. Wash clothing before reuse. Clean shoes thoroughly before reuse.

Antibodies Reagent IVD

SECTION 4: First aid measures

- Ingestion** : Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

Over-exposure signs/symptoms

- Eye contact** : No specific data.
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Specific treatments** : No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : None known.

5.2 Special hazards arising from the substance or mixture

- Hazards from the substance or mixture** : In a fire or if heated, a pressure increase will occur and the container may burst. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.
- Hazardous combustion products** : Decomposition products may include the following materials:
nitrogen oxides
halogenated compounds
metal oxide/oxides

5.3 Advice for firefighters

- Special precautions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

Antibodies Reagent IVD

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
- For emergency responders** : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

- 6.2 Environmental precautions** : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

6.3 Methods and material for containment and cleaning up

- Methods for cleaning up** : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

- 6.4 Reference to other sections** : See Section 1 for emergency contact information.
See Section 8 for information on appropriate personal protective equipment.
See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8). Do not ingest. Avoid contact with eyes, skin and clothing. Avoid breathing vapour or mist. Avoid release to the environment. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

- Storage** : Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

- Recommendations** : Industrial applications, Professional applications.
- Industrial sector specific solutions** : Not available.

Antibodies Reagent IVD

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values
Sodium azide	NAOSH (Ireland, 1/2020). Absorbed through skin. OELV-8hr: 0.1 mg/m ³ , (as NaN ₃) 8 hours. OELV-15min: 0.3 mg/m ³ , (as NaN ₃) 15 minutes.

Recommended monitoring procedures : If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

No DNELs/DMELs available.

PNECs

No PNECs available

8.2 Exposure controls

Appropriate engineering controls : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

Hygiene measures : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Body protection : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Antibodies Reagent IVD

SECTION 8: Exposure controls/personal protection

Environmental exposure controls : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance

- Physical state** : Liquid.
- Colour** : Not available.
- Odour** : Not available.
- Odour threshold** : Not available.
- Melting point/freezing point** : 0°C
- Initial boiling point and boiling range** : 100°C (212°F)
- Flammability (solid, gas)** : Not applicable.
- Upper/lower flammability or explosive limits** : Not available.
- Flash point** : Not available.

Auto-ignition temperature	Ingredient name	°C	°F	Method
	Sodium azide	309	588.2	EU A.16

- Decomposition temperature** : Not available.
- pH** : Not available.
- Viscosity** : Not available.
- Solubility(ies)** : Easily soluble in the following materials: cold water and hot water.
- Miscible with water** : Yes.
- Partition coefficient: n-octanol/water** : Not applicable.

Vapour pressure	Ingredient name	Vapour Pressure at 20°C			Vapour pressure at 50°C		
		mm Hg	kPa	Method	mm Hg	kPa	Method
	water	23.8	3.2		92.258	12.3	
	Sodium azide	0.0075	0.001				

- Evaporation rate** : Not available.
- Relative density** : Not available.
- Vapour density** : Not available.
- Explosive properties** : Not available.
- Oxidising properties** : Not available.

Particle characteristics

- Median particle size** : Not applicable.

No additional information.

Antibodies Reagent IVD

SECTION 10: Stability and reactivity

- 10.1 Reactivity** : No specific test data related to reactivity available for this product or its ingredients.
- 10.2 Chemical stability** : The product is stable.
- 10.3 Possibility of hazardous reactions** : Under normal conditions of storage and use, hazardous reactions will not occur.
- 10.4 Conditions to avoid** : No specific data.
- 10.5 Incompatible materials** : May react or be incompatible with oxidising materials.
- 10.6 Hazardous decomposition products** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
Sodium azide	LC50 Inhalation Dusts and mists	Rat - Male, Female	0.054 to 0.52 mg/	4 hours
	LD50 Dermal	Rabbit	20 mg/kg	-
	LD50 Dermal	Rat	50 mg/kg	-
	LD50 Oral	Rat	27 mg/kg	-

Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
Antibodies Reagent IVD	2700	N/A	N/A	N/A	N/A
Sodium azide	27	N/A	N/A	N/A	N/A

Irritation/Corrosion

Conclusion/Summary : Not available.

Sensitiser

Conclusion/Summary : Not available.

Mutagenicity

Conclusion/Summary : Not available.

Carcinogenicity

Conclusion/Summary : Not available.

Reproductive toxicity

Conclusion/Summary : Not available.

Teratogenicity

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Antibodies Reagent IVD

SECTION 11: Toxicological information

Information on likely routes of exposure : Not available.

Potential acute health effects

- Inhalation** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Eye contact** : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

- Inhalation** : No specific data.
- Ingestion** : No specific data.
- Skin contact** : No specific data.
- Eye contact** : No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

- Potential immediate effects** : Not available.
- Potential delayed effects** : Not available.

Long term exposure

- Potential immediate effects** : Not available.
- Potential delayed effects** : Not available.

Potential chronic health effects

- General** : No known significant effects or critical hazards.
- Carcinogenicity** : No known significant effects or critical hazards.
- Mutagenicity** : No known significant effects or critical hazards.
- Reproductive toxicity** : No known significant effects or critical hazards.

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
Sodium azide	Acute EC50 9200 µg/l Marine water	Algae - <i>Macrocystis pyrifera</i>	96 hours
	Acute EC50 6.4 mg/l Fresh water	Crustaceans - <i>Simocephalus serrulatus</i> - Larvae	48 hours
	Acute EC50 4.2 mg/l Fresh water	Daphnia - <i>Daphnia pulex</i> - Larvae	48 hours
	Acute LC50 0.68 mg/l Fresh water	Fish - <i>Lepomis macrochirus</i>	96 hours
	Chronic NOEC 5600 µg/l Marine water	Algae - <i>Macrocystis pyrifera</i>	96 hours

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

- Soil/water partition coefficient (K_{oc})** : Not available.
- Mobility** : Not available.

Antibodies Reagent IVD

SECTION 12: Ecological information

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste : The classification of the product may meet the criteria for a hazardous waste.

Packaging

Methods of disposal : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Special precautions : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	IMDG	IATA
14.1 UN number	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-
14.3 Transport hazard class(es)	-	-	-
14.4 Packing group	-	-	-
14.5 Environmental hazards	No.	No.	No.

Additional information

14.6 Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments : Not available.

Antibodies Reagent IVD

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Label : Not applicable.

Other EU regulations

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Persistent Organic Pollutants

Not listed.

Seveso Directive

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Australia	: Not determined.
Canada	: Not determined.
China	: All components are listed or exempted.
Europe	: All components are listed or exempted.
Japan	: Japan inventory (CSCL) : Not determined. Japan inventory (ISHL) : Not determined.
New Zealand	: Not determined.
Philippines	: Not determined.
Republic of Korea	: Not determined.
Taiwan	: All components are listed or exempted.
Thailand	: Not determined.
Turkey	: Not determined.
United States	: All components are active or exempted.
Viet Nam	: Not determined.

Antibodies Reagent IVD

SECTION 15: Regulatory information

15.2 Chemical safety assessment : This product contains substances for which Chemical Safety Assessments might still be required.

SECTION 16: Other information

✔ Indicates information that has changed from previously issued version.

Abbreviations and acronyms : ATE = Acute Toxicity Estimate
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level
EUH statement = CLP-specific Hazard statement
N/A = Not available
PBT = Persistent, Bioaccumulative and Toxic
PNEC = Predicted No Effect Concentration
RRN = REACH Registration Number
vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Aquatic Chronic 3, H412	Calculation method

Full text of abbreviated H statements

H300 H400 H410 H412 EUH032	Fatal if swallowed. Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects. Harmful to aquatic life with long lasting effects. Contact with acids liberates very toxic gas.
--	---

Full text of classifications [CLP/GHS]

Acute Tox. 2 Aquatic Acute 1 Aquatic Chronic 1 Aquatic Chronic 3	ACUTE TOXICITY - Category 2 SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
---	---

Date of issue/ Date of revision : 23/06/2022

Date of previous issue : No previous validation

Version : 1

Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.